Cargando…
Erlotinib inhibits osteolytic bone invasion of human non-small-cell lung cancer cell line NCI-H292
Previous preclinical and clinical findings have suggested a potential role of epidermal growth factor receptor (EGFR) in osteoclast differentiation and the pathogenesis of bone metastasis in cancer. In this study, we investigated the effect of erlotinib, an orally active EGFR tyrosine kinase inhibit...
Autores principales: | Furugaki, Koh, Moriya, Yoichiro, Iwai, Toshiki, Yorozu, Keigo, Yanagisawa, Mieko, Kondoh, Kumiko, Fujimoto-Ohuchi, Kaori, Mori, Kazushige |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198194/ https://www.ncbi.nlm.nih.gov/pubmed/21688034 http://dx.doi.org/10.1007/s10585-011-9398-4 |
Ejemplares similares
-
Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model
por: Masuda, Chinami, et al.
Publicado: (2017) -
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
por: IWAI, TOSHIKI, et al.
Publicado: (2011) -
Biomarkers for antitumor activity of bevacizumab in gastric cancer models
por: Yamashita-Kashima, Yoriko, et al.
Publicado: (2012) -
NCI-H292 as an alternative cell line for the isolation and propagation of the human paramyxoviruses
por: Castells, Empar, et al.
Publicado: (1990) -
lncRNA profiling in NCI-H292 cells after stimulation with
Dermatophagoides farinae extracts
por: Wang, Lilei, et al.
Publicado: (2018)